BGC
ANIP icon

Birch Grove Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Birch Grove Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,791
Closed -$1.43M – 41
2020
Q3 		$1.43M Buy
+50,791
New +$1.51M 0.78% 36

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Birch Grove Capital's ANIP Position: Q4 2020 in Review

Birch Grove Capital sold out of ANI Pharmaceuticals (ANIP) in Q4 2020, closing a stake of 50,791 shares — an estimated $1.43M sold.

Birch Grove Capital first reported a position in ANIP in Q3 2020 and held it in 1 quarter. The position peaked at $1.43M in Q3 2020. 117 funds tracked by Wall St. Rank hold ANIP as of Q4 2020.

  • Birch Grove Capital reported no remaining ANI Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Birch Grove Capital sold 50,791 ANI Pharmaceuticals shares in Q4 2020, an estimated $1.43M.
  • Birch Grove Capital first reported a position in ANI Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Birch Grove Capital's ANI Pharmaceuticals position peaked at $1.43M in Q3 2020.
  • 117 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2020.

Based on Birch Grove Capital's 13F filing for Q4 2020, filed 16 Feb 2021.